DEF: Aquestive Therapeutics 2026 Annual Meeting Proxy

Aquestive Therapeutics announces its 2026 Annual Meeting of Stockholders to be held virtually on June 10, 2026.

Summary

• The 2026 Annual Meeting of Stockholders is scheduled for June 10, 2026, at 9:30 a.m. ET in a virtual-only format.
• Stockholders will vote on the election of three Class II directors, an advisory vote on executive compensation, and the ratification of KPMG LLP as the independent auditor.
• The record date for voting eligibility was April 13, 2026, with 124,284,542 shares of common stock outstanding.
• The company operates as a smaller reporting company, allowing for reduced disclosure obligations.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing for an annual meeting, reflecting standard corporate governance procedures without significant new strategic or financial shifts.

Positives

• The company maintains a clear, performance-based executive compensation structure.
• The board maintains a high level of independence, with six out of seven directors being independent.
• The company has established clear governance guidelines and committee charters to oversee risk and strategy.

Negatives

• The company reported negative net income for the fiscal years 2023, 2024, and 2025.
• There were instances of late Section 16(a) filings for several executives and directors during 2025.

Risks

• The company faces risks inherent in the pharmaceutical industry, including the long time horizon for product development and regulatory hurdles.
• The company is subject to liquidity risks and must manage its capital resources effectively.
• The company faces potential cybersecurity risks as noted in the Audit Committee's oversight responsibilities.

Future Outlook

The company remains focused on advancing its proprietary products in 2026 and continues to pursue its strategic growth plans.

Management Comments

• We are pleased with what we have accomplished during the past year, and we remain focused on advancing our proprietary products in 2026.
• We are excited for the opportunities that lie ahead for us as a pharmaceutical company.

Industry Context

StockSavvy.ai notes that Aquestive's virtual-only meeting format and classified board structure are common practices among small-cap biopharmaceutical companies seeking to maintain leadership stability during long-term R&D cycles.

Comparison to Industry Standards

• The company's executive compensation structure aligns with standard industry practices for smaller reporting companies.
• The use of a classified board is a standard mechanism in the biotech sector to resist short-term pressure and focus on long-term drug development timelines.

Management Changes

Corporate Governance

Legal Proceedings

• None disclosed.

Related Party Transactions

• Registration rights granted to various directors and officers.
• Indemnification agreements with directors and executive officers.

Stakeholder Impact

• Shareholders are requested to vote on director elections and executive compensation.
• Employees and management are subject to the company's updated equity incentive plans and governance policies.

Next Steps

• Hold the 2026 Annual Meeting of Stockholders on June 10, 2026.
• File final voting results in a Form 8-K within four business days after the meeting.

Key Dates

Keywords

Aquestive Therapeutics, Proxy Statement, Annual Meeting, Biopharmaceutical, Corporate Governance, Executive Compensation, AQST